Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 17 Aug 2024
Reviewer's report:
The disease spectrum of MASLD includes simple steatosis, steatohepatitis, liver fibrosis, and
cirrhosis. Among these, what is related to the prognosis of the disease is the presence or absence
of MASH or liver fibrosis in particular. It is difficult to say that the increase in steatosis represents
the degree of progression of liver disease.
Besides measuring the degree of steatosis using MRI-PDFF, have you tried measuring changes
in liver stiffness measurement using Fibroscan or MR elastography?
Please add an evaluation of the usefulness of non-invasive markers related to changes of
liver stiffness measurement using Fibroscan or MR elastography or changes of NAS score on
pathologic confirmation.
If you can't provide data like this, it is difficult to consider the results of this study as a
comparative study of markers useful for assessing the progression of liver disease.
Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 17 Aug 2024
Reviewer's report:
The disease spectrum of MASLD includes simple steatosis, steatohepatitis, liver fibrosis, and
cirrhosis. Among these, what is related to the prognosis of the disease is the presence or absence
of MASH or liver fibrosis in particular. It is difficult to say that the increase in steatosis represents
the degree of progression of liver disease.
Besides measuring the degree of steatosis using MRI-PDFF, have you tried measuring changes
in liver stiffness measurement using Fibroscan or MR elastography?
Please add an evaluation of the usefulness of non-invasive markers related to changes of
liver stiffness measurement using Fibroscan or MR elastography or changes of NAS score on
pathologic confirmation.
If you can't provide data like this, it is difficult to consider the results of this study as a
comparative study of markers useful for assessing the progression of liver disease.
Please review this paper.
user
Title: Evaluating the Efficacy of 8 Non-invasive Models in Predicting MASLD and Its
Progression: A Prospective Study
Version: 3 Date: 17 Aug 2024
Reviewer's report:
The disease spectrum of MASLD includes simple steatosis, steatohepatitis, liver fibrosis, and
cirrhosis. Among these, what is related to the prognosis of the disease is the presence or absence
of MASH or liver fibrosis in particular. It is difficult to say that the increase in steatosis represents
the degree of progression of liver disease.
Besides measuring the degree of steatosis using MRI-PDFF, have you tried measuring changes
in liver stiffness measurement using Fibroscan or MR elastography?
Please add an evaluation of the usefulness of non-invasive markers related to changes of
liver stiffness measurement using Fibroscan or MR elastography or changes of NAS score on
pathologic confirmation.
If you can't provide data like this, it is difficult to consider the results of this study as a
comparative study of markers useful for assessing the progression of liver disease.
assistant